• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

二羧酸与人体钠二羧酸协同转运蛋白 3 和有机阴离子转运蛋白 1、3 的差异相互作用。

Differential interaction of dicarboxylates with human sodium-dicarboxylate cotransporter 3 and organic anion transporters 1 and 3.

机构信息

Abteilung Vegetative Physiologie und Pathophysiologie, Universitätsmedizin Göttingen, Göttingen, Germany.

出版信息

Am J Physiol Renal Physiol. 2011 Nov;301(5):F1026-34. doi: 10.1152/ajprenal.00169.2011. Epub 2011 Aug 24.

DOI:10.1152/ajprenal.00169.2011
PMID:21865262
Abstract

Organic anions are taken up from the blood into proximal tubule cells by organic anion transporters 1 and 3 (OAT1 and OAT3) in exchange for dicarboxylates. The released dicarboxylates are recycled by the sodium dicarboxylate cotransporter 3 (NaDC3). In this study, we tested the substrate specificities of human NaDC3, OAT1, and OAT3 to identify those dicarboxylates for which the three cooperating transporters have common high affinities. All transporters were stably expressed in HEK293 cells, and extracellularly added dicarboxylates were used as inhibitors of [(14)C]succinate (NaDC3), p-[(3)H]aminohippurate (OAT1), or [(3)H]estrone-3-sulfate (OAT3) uptake. Human NaDC3 was stably expressed as proven by immunochemical methods and by sodium-dependent uptake of succinate (K(0.5) for sodium activation, 44.6 mM; Hill coefficient, 2.1; K(m) for succinate, 18 μM). NaDC3 was best inhibited by succinate (IC(50) 25.5 μM) and less by α-ketoglutarate (IC(50) 69.2 μM) and fumarate (IC(50) 95.2 μM). Dicarboxylates with longer carbon backbones (adipate, pimelate, suberate) had low or no affinity for NaDC3. OAT1 exhibited the highest affinity for glutarate, α-ketoglutarate, and adipate (IC(50) between 3.3 and 6.2 μM), followed by pimelate (18.6 μM) and suberate (19.3 μM). The affinity of OAT1 to succinate and fumarate was low. OAT3 showed the same dicarboxylate selectivity with ∼13-fold higher IC(50) values compared with OAT1. The data 1) reveal α-ketoglutarate as a common high-affinity substrate of NaDC3, OAT1, and OAT3 and 2) suggest potentially similar molecular structures of the binding sites in OAT1 and OAT3 for dicarboxylates.

摘要

有机阴离子通过有机阴离子转运体 1 和 3(OAT1 和 OAT3)从血液中摄取到近曲小管细胞中,以交换二羧酸。释放的二羧酸被二羧酸钠协同转运蛋白 3(NaDC3)回收。在这项研究中,我们测试了人源 NaDC3、OAT1 和 OAT3 的底物特异性,以确定这三种协同转运体具有共同高亲和力的二羧酸。所有转运体均稳定表达于 HEK293 细胞中,并用细胞外添加的二羧酸作为[14C]琥珀酸盐(NaDC3)、对[3H]氨基马尿酸(OAT1)或[3H]雌酮-3-硫酸盐(OAT3)摄取的抑制剂。通过免疫化学方法和钠依赖性琥珀酸盐摄取证实人源 NaDC3 稳定表达(钠离子激活的 K0.5 为 44.6 mM;Hill 系数为 2.1;琥珀酸盐的 K(m)为 18 μM)。NaDC3 被琥珀酸盐(IC50 为 25.5 μM)强烈抑制,而被α-酮戊二酸(IC50 为 69.2 μM)和富马酸(IC50 为 95.2 μM)抑制作用较弱。具有较长碳骨架的二羧酸(己二酸、庚二酸、辛二酸)对 NaDC3 的亲和力低或没有。OAT1 对戊二酸盐、α-酮戊二酸和己二酸表现出最高的亲和力(IC50 在 3.3 到 6.2 μM 之间),其次是庚二酸(18.6 μM)和辛二酸(19.3 μM)。OAT1 对琥珀酸盐和富马酸盐的亲和力较低。OAT3 对二羧酸的选择性与 OAT1 相同,但 IC50 值高 13 倍。该数据揭示了 α-酮戊二酸是 NaDC3、OAT1 和 OAT3 的共同高亲和力底物,并且提示 OAT1 和 OAT3 中二羧酸结合位点可能具有相似的分子结构。

相似文献

1
Differential interaction of dicarboxylates with human sodium-dicarboxylate cotransporter 3 and organic anion transporters 1 and 3.二羧酸与人体钠二羧酸协同转运蛋白 3 和有机阴离子转运蛋白 1、3 的差异相互作用。
Am J Physiol Renal Physiol. 2011 Nov;301(5):F1026-34. doi: 10.1152/ajprenal.00169.2011. Epub 2011 Aug 24.
2
Distribution of organic anion transporters NaDC3 and OAT1-3 along the human nephron.有机阴离子转运体NaDC3和OAT1 - 3在人肾单位中的分布。
Am J Physiol Renal Physiol. 2016 Jul 1;311(1):F227-38. doi: 10.1152/ajprenal.00113.2016. Epub 2016 Apr 6.
3
Transporters involved in renal excretion of N-carbamoylglutamate, an orphan drug to treat inborn n-acetylglutamate synthase deficiency.参与 N-氨甲酰谷氨酸肾脏排泄的转运体,一种用于治疗先天性 N-乙酰谷氨酸合酶缺乏症的孤儿药物。
Am J Physiol Renal Physiol. 2014 Dec 15;307(12):F1373-9. doi: 10.1152/ajprenal.00482.2014. Epub 2014 Oct 29.
4
α-Ketoglutarate-related inhibitors of HIF prolyl hydroxylases are substrates of renal organic anion transporters 1 (OAT1) and 4 (OAT4).α-酮戊二酸相关的 HIF 脯氨酰羟化酶抑制剂是肾脏有机阴离子转运体 1(OAT1)和 4(OAT4)的底物。
Pflugers Arch. 2012 Oct;464(4):367-74. doi: 10.1007/s00424-012-1140-9. Epub 2012 Aug 9.
5
Substrate specificity of the human renal sodium dicarboxylate cotransporter, hNaDC-3, under voltage-clamp conditions.电压钳制条件下人肾二羧酸钠协同转运蛋白hNaDC-3的底物特异性
Am J Physiol Renal Physiol. 2005 Apr;288(4):F792-9. doi: 10.1152/ajprenal.00360.2004. Epub 2004 Nov 23.
6
Organic anion transporters OAT1 and OAT4 mediate the high affinity transport of glutarate derivatives accumulating in patients with glutaric acidurias.有机阴离子转运体OAT1和OAT4介导戊二酸尿症患者体内蓄积的戊二酸衍生物的高亲和力转运。
Pflugers Arch. 2008 Oct;457(1):223-31. doi: 10.1007/s00424-008-0489-2. Epub 2008 Mar 26.
7
Differential Interaction of Dantrolene, Glafenine, Nalidixic Acid, and Prazosin with Human Organic Anion Transporters 1 and 3.丹曲林、格拉非宁、萘啶酸和哌唑嗪与人有机阴离子转运体1和3的差异相互作用。
J Pharmacol Exp Ther. 2017 Sep;362(3):450-458. doi: 10.1124/jpet.117.241406. Epub 2017 Jun 19.
8
Organic anion transporter 3 (Slc22a8) is a dicarboxylate exchanger indirectly coupled to the Na+ gradient.有机阴离子转运体3(Slc22a8)是一种间接与钠离子梯度偶联的二羧酸交换体。
Am J Physiol Renal Physiol. 2003 Apr;284(4):F763-9. doi: 10.1152/ajprenal.00405.2002. Epub 2002 Dec 17.
9
A renal-like organic anion transport system in the ciliary epithelium of the bovine and human eye.牛和人眼睫状体上皮中的一种类似肾脏的有机阴离子转运系统。
Mol Pharmacol. 2015 Apr;87(4):697-705. doi: 10.1124/mol.114.096578. Epub 2015 Feb 6.
10
Relative contribution of OAT1 and OAT3 transport activities in isolated perfused rabbit renal proximal tubules.OAT1和OAT3转运活性在离体灌注兔肾近端小管中的相对贡献。
Biochim Biophys Acta. 2006 Jun;1758(6):789-95. doi: 10.1016/j.bbamem.2006.05.012. Epub 2006 May 20.

引用本文的文献

1
Substrate translocation and inhibition in human dicarboxylate transporter NaDC3.人二羧酸转运体NaDC3中的底物转运与抑制
Nat Struct Mol Biol. 2025 Mar;32(3):502-512. doi: 10.1038/s41594-024-01433-0. Epub 2024 Dec 2.
2
The substrate and inhibitor binding mechanism of polyspecific transporter OAT1 revealed by high-resolution cryo-EM.高分辨率冷冻电镜解析多药耐药相关蛋白 OAT1 的底物和抑制剂结合机制。
Nat Struct Mol Biol. 2023 Nov;30(11):1794-1805. doi: 10.1038/s41594-023-01123-3. Epub 2023 Oct 16.
3
Structural and functional implications of SLC13A3 and SLC9A6 mutations: an in silico approach to understanding intellectual disability.
SLC13A3 和 SLC9A6 突变的结构和功能意义:一种理解智力障碍的计算方法。
BMC Neurol. 2023 Oct 4;23(1):353. doi: 10.1186/s12883-023-03397-y.
4
A Novel and Cross-Species Active Mammalian INDY (NaCT) Inhibitor Ameliorates Hepatic Steatosis in Mice with Diet-Induced Obesity.一种新型的跨物种活性哺乳动物INDY(NaCT)抑制剂可改善饮食诱导肥胖小鼠的肝脂肪变性。
Metabolites. 2022 Aug 8;12(8):732. doi: 10.3390/metabo12080732.
5
Case Report: Compound Heterozygous Variants of Identified in a Chinese Patient With Acute Reversible Leukoencephalopathy and α-Ketoglutarate Accumulation.病例报告:在中国一名患有急性可逆性白质脑病和α-酮戊二酸蓄积的患者中鉴定出的复合杂合变异体。
Front Pediatr. 2021 Dec 13;9:801719. doi: 10.3389/fped.2021.801719. eCollection 2021.
6
Thermostability-based binding assays reveal complex interplay of cation, substrate and lipid binding in the bacterial DASS transporter, VcINDY.基于热稳定性的结合分析揭示了细菌 DASS 转运蛋白 VcINDY 中阳离子、底物和脂质结合的复杂相互作用。
Biochem J. 2021 Nov 12;478(21):3847-3867. doi: 10.1042/BCJ20210061.
7
Signals from the Circle: Tricarboxylic Acid Cycle Intermediates as Myometabokines.循环发出的信号:三羧酸循环中间产物作为子宫代谢因子
Metabolites. 2021 Jul 23;11(8):474. doi: 10.3390/metabo11080474.
8
C9orf72 expansion within astrocytes reduces metabolic flexibility in amyotrophic lateral sclerosis.星形胶质细胞内 C9orf72 扩展减少肌萎缩侧索硬化症的代谢灵活性。
Brain. 2019 Dec 1;142(12):3771-3790. doi: 10.1093/brain/awz302.
9
Counter-flow suggests transport of dantrolene and 5-OH dantrolene by the organic anion transporters 2 (OAT2) and 3 (OAT3).逆流表明有机阴离子转运体2(OAT2)和3(OAT3)可转运丹曲林和5-羟基丹曲林。
Pflugers Arch. 2016 Nov;468(11-12):1909-1918. doi: 10.1007/s00424-016-1894-6. Epub 2016 Nov 3.
10
Mutations in the Na(+)/citrate cotransporter NaCT (SLC13A5) in pediatric patients with epilepsy and developmental delay.患有癫痫和发育迟缓的儿科患者中,钠离子/柠檬酸盐共转运体NaCT(SLC13A5)的突变。
Mol Med. 2016 May 26;22:310-21. doi: 10.2119/molmed.2016.00077.